Drugs / Monovalent Avian Influenza VLP (H7N9)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01897701 | Jul 2013 → Aug 2014 | avian influenza | Novavax | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02078674 | Mar 2014 → Jul 2015 | influenza | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent Avian Influenza VLP (H7N9) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01897701 ↗ |
| Modality | Vaccine | “A recombinant viruslike particle influenza A (H7N9) vaccine.” PMID 24224560 ↗ Nov 2013 |
| Route | Intramuscular | “Treatments will comprise two identical IM doses at a 21-day interval (Day 0 and Day 21), in alternate deltoids.” NCT01897701 ↗ |